GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BiomX Inc.
BiomX is a biotech company developing bacteriophage-based therapies. Its stock price is a bet that this approach will become an effective alternative to antibiotics. The stock price reflects high volatility and dependence on clinical trial news.
Share prices of companies in the market segment - Pharma infections
BiomX is a biotech company developing bacteriophage-based drugs for the treatment of chronic bacterial diseases, such as acne and atopic dermatitis. We've categorized it under "Pharma: Infections," and the chart below shows the dynamics of the bacterial infection sector.
Broad Market Index - GURU.Markets
BiomX is an Israeli biotech company developing bacteriophage-based drugs for the treatment of bacterial diseases. As an innovator in this field, it is included in our GURU.Markets index. The chart below shows the overall market trend. Compare it with BiomX's performance to assess the state of this sector.
Change in the price of a company, segment, and market as a whole per day
PHGE - Daily change in the company's share price BiomX Inc.
For BiomX Inc., which develops bacteriophage-based drugs, daily volatility reflects sensitivity to clinical trial data. This metric is key for assessing risks in the innovative field of infection treatment.
Daily change in the price of a set of shares in a market segment - Pharma infections
BiomX Inc. is a biotech company. This chart shows the extreme volatility of the sector. Comparison with the performance of PHGE, which focuses on bacteriophage therapy, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
BiomX is an Israeli biotech company developing bacteriophage-based therapies to combat bacteria. Its shares are driven by research news. This high volatility, driven by innovation, is a significant contributor to the overall "noise" and dynamics of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BiomX Inc.
For BiomX Inc., the year-to-date performance is a story about the development of bacteriophage-based therapies. Its 12-month market cap is entirely dependent on clinical trial data for its acne and cystic fibrosis treatments. Success could offer a new way to combat antibiotic-resistant bacterial infections.
Annual dynamics of market capitalization of the market segment - Pharma infections
BiomX Inc. is an Israeli biotechnology company developing bacteriophage-based therapeutics. Its stock price is highly volatile, reflecting investor confidence in its breakthrough scientific potential and ability to commercialize its unique technology to combat bacterial infections.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BiomX, which is developing bacteriophage-based therapies, is betting on an alternative to antibiotics. Its performance relative to the market demonstrates the level of investor confidence in this cutting-edge scientific concept. Success in clinical trials could make it a leader in a new era of medicine and lead to significant market outperformance.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BiomX Inc.
BiomX is a biotech company developing phage therapy. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its treatment programs for acne, atopic dermatitis, and other conditions is a key event for investors.
Monthly dynamics of market capitalization of the market segment - Pharma infections
BiomX is a biotech company developing bacteriophage-based drugs for the treatment of chronic bacterial diseases, such as acne and atopic dermatitis. The graph below shows the dynamics of the biotech sector, where microbiome-based therapies are a new and promising area.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BiomX is a biotech company developing bacteriophage-based therapies to combat bacterial diseases. This is a cutting-edge field of medicine. The company's shares are driven by news of clinical trials, and their performance is completely disconnected from overall market sentiment.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BiomX Inc.
BiomX is developing bacteriophage-based therapies for the treatment of microbiome-related diseases. Its weekly stock price reflects progress in this cutting-edge, yet risky, field of medicine. Clinical data is the main driver.
Weekly dynamics of market capitalization of the market segment - Pharma infections
BiomX Inc. fights infections with bacteriophages. This is cutting-edge science. The chart helps us understand: are the company's weekly stock price fluctuations a reaction to unique research findings or are they following the general trend in the infectious disease biotech sector?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BiomX Inc. is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
PHGE - Market capitalization of the company BiomX Inc.
BiomX's market capitalization is a bet on bacteriophage-based therapies. This biotech company's chart reflects investors' belief that "good" viruses may hold the key to treating bacterial infections, especially those resistant to antibiotics. It's a story of cutting-edge science.
PHGE - Share of the company's market capitalization BiomX Inc. within the market segment - Pharma infections
BiomX is a biotech company developing phage-based drugs (viruses that infect bacteria) to treat diseases caused by antibiotic-resistant bacteria. Its market capitalization in the infectious disease pharmaceuticals segment reflects the potential of this innovative approach. The company's size reflects its bet that phage therapy will be the solution to the problem of antibiotic resistance.
Market capitalization of the market segment - Pharma infections
BiomX is a leader in phage therapy development. How big is this new arena? The chart below shows the overall market capitalization of the infectious pharmaceutical sector. Its dynamics reflect the growing threat of antibiotic resistance and the search for alternative ways to combat bacterial infections.
Market capitalization of all companies included in a broad market index - GURU.Markets
The BiomX chart shows how the market values therapies based on bacteriophages—viruses that kill bacteria. The company's market cap reflects a bet that this approach will solve the problem of antibiotic resistance. This diagram illustrates how an old idea can gain new life in modern medicine.
Book value capitalization of the company, segment and market as a whole
PHGE - Book value capitalization of the company BiomX Inc.
For BiomX, a company developing bacteriophage-based therapies, book value is its physical foundation: laboratories, phage production facilities, and financial reserves for R&D. The chart below shows how the company built this physical foundation to combat bacterial infections.
PHGE - Share of the company's book capitalization BiomX Inc. within the market segment - Pharma infections
BiomX Inc. is a company developing bacteriophage-based therapeutics. Its key assets are cutting-edge laboratories and manufacturing facilities for identifying and producing these "good" viruses. The chart shows the share of this unique microbiological infrastructure the company controls.
Market segment balance sheet capitalization - Pharma infections
BiomX is a company developing phage-based therapeutics. Pharmaceuticals, as the chart shows, are capital-intensive. BiomX is a prime example. Its business requires building its own complex and expensive factories to produce its drugs.
Book value of all companies included in the broad market index - GURU.Markets
BiomX's assets are not antibiotics, but a scientific platform for developing drugs based on bacteriophages (viruses that infect bacteria) for the treatment of microbiome-related diseases, such as acne and cystic fibrosis. Its book value reflects its laboratory base.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BiomX Inc.
BiomX is a biotech company developing phage-based (bacteria-killing viruses) therapies for microbiome-related diseases. Its value lies in its unique scientific platform. The chart shows how the market is valuing this cutting-edge approach to treating acne and other conditions.
Market to book capitalization ratio in a market segment - Pharma infections
BiomX develops phage-based (bacteria-infecting viruses) treatments for microbiome-related diseases. This is cutting-edge science. The chart shows how the market views its unique technology platform and potential for combating bacterial infections.
Market to book capitalization ratio for the market as a whole
BiomX is developing bacteriophage-based therapies. Investors value the uniqueness of the technology and patents, not lab equipment. This chart shows how the market values innovative approaches in medicine, awarding high marks to companies that can create entirely new classes of drugs.
Debts of the company, segment and market as a whole
PHGE - Company debts BiomX Inc.
BiomX develops bacteriophage-based treatments for bacterial diseases. This innovative approach requires significant investment in research and clinical trials. This chart shows how the company is raising capital to finance its unique scientific platform and advance phage therapy toward potential approval.
Market segment debts - Pharma infections
BiomX is a clinical-stage biotechnology company developing bacteriophage-based therapies to combat bacterial infections. This innovative approach requires significant investment in R&D. This chart shows its financial position and reliance on equity capital to fund its unique research programs.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BiomX Inc.
BiomX Inc. develops bacteriophage-based drugs. This chart shows the financial structure of the biotech company. For a company working with cutting-edge but unproven technology, raising debt is an extremely risky strategy. Success depends on scientific breakthroughs, not financial leverage.
Market segment debt to market segment book capitalization - Pharma infections
BiomX is a pioneer in developing bacteriophage-based therapies for the treatment of diseases caused by antibiotic-resistant bacteria. This is a promising but complex field. The chart shows the overall debt burden in the pharmaceutical industry, which helps understand how BiomX finances its innovative but risky clinical trials.
Debt to book value of all companies in the market
BiomX Inc. is a biotechnology company developing bacteriophage-based therapeutics, a new approach to treating infections. Currently in clinical trials, BiomX is entirely dependent on equity capital. This chart highlights the gap between the investor-funded world of cutting-edge science and the debt-fueled world of traditional business.
P/E of the company, segment and market as a whole
P/E - BiomX Inc.
This metric for BiomX, a biotech company developing bacteriophage-based therapies, reflects faith in the new technology. P/E ratios are not applicable here. The company's valuation is a bet that its approach to treating bacterial infections will succeed where antibiotics fail.
P/E of the market segment - Pharma infections
BiomX is a clinical-stage biotechnology company developing bacteriophage-based therapies for the treatment of chronic bacterial diseases, such as acne and atopic dermatitis. This chart shows the average valuation for the sector, helping to understand how the market views this innovative approach to combating bacterial infections.
P/E of the market as a whole
BiomX is a biotech company developing bacteriophage-based therapies for the treatment of bacterial diseases. Its valuation is a bet on this innovative technology. It is not tied to the general economic cycles shown by this chart, but depends on the success of its clinical trials and its ability to combat antibiotic-resistant bacteria.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BiomX Inc.
BiomX is a biotech company developing bacteriophage-based drugs for the treatment of chronic bacterial diseases. This chart reflects investor expectations for clinical trials in areas such as acne and cystic fibrosis. The valuation is based on the potential of phage therapy to become an alternative to antibiotics.
%20P%2FE%20BiomX%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BiomX-Inc.&v=1772585277848 "Chart of the company's future (projected) P/E BiomX Inc.")
Future (projected) P/E of the market segment - Pharma infections
BiomX is a biotech company developing bacteriophage-based therapies for the treatment of bacterial diseases such as acne and cystic fibrosis. Its valuation relative to other biotechs reflects investors' views on the potential of its unique platform, a bet that phage therapy will become a viable alternative to antibiotics.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-infections&v=1772585277854 "Future (projected) P/E graph of the market segment - Pharma infections")
Future (projected) P/E of the market as a whole
BiomX is a biotech company developing bacteriophage-based drugs (viruses that infect bacteria) to treat microbiome-related diseases. This is a cutting-edge field, but one that has yet to be proven effective. This chart shows the overall risk appetite. For companies with innovative platforms like BiomX, positive investor sentiment is crucial.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772585277861 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BiomX Inc.
BiomX is a biotechnology company developing bacteriophage-based therapies for the treatment of chronic diseases caused by bacteria. The financial indicators reflected here represent investments in clinical research. Success depends on the ability of its phage therapy to prove its effectiveness.
Profit of companies in the market segment - Pharma infections
BiomX Inc. is developing bacteriophage-based therapies for the treatment of chronic diseases caused by bacteria. This chart shows the total revenue in the infectious disease pharmaceutical sector. It helps understand whether this innovative phage-based approach is a commercially viable alternative to traditional antibiotics.
Overall market profit
BiomX develops bacteriophage-based drugs for the treatment of chronic diseases caused by bacteria. This is an innovative approach to medicine. The company's success depends on the results of clinical trials and regulatory approval. Macroeconomic cycles, visible in this graph, have virtually no impact on PHGE's scientific process.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BiomX Inc.
BiomX is a biotech company developing bacteriophage-based therapies for the treatment of bacterial-related diseases, including acne and intestinal disorders. Profit projections are dependent on the success of clinical trials. This chart reflects analysts' belief in the potential of phage therapy to become a new approach to medicine.
%20profit%20of%20the%20company%20BiomX%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BiomX-Inc.&v=1772585277909 "Graph of future (projected) profit of the company BiomX Inc.")
Future (predicted) profit of companies in the market segment - Pharma infections
BiomX is a biotechnology company developing bacteriophage-based drugs (viruses that infect bacteria) for the treatment of chronic bacterial diseases such as acne and atopic dermatitis. This chart shows forecasts for the pharmaceutical segment. It illustrates the potential of new approaches, such as phage therapy, in the fight against antibiotic-resistant infections.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-infections&v=1772585277957 "Graph of future (predicted) profits of companies in a market segment - Pharma infections")
Future (predicted) profit of the market as a whole
This chart shows investors' willingness to fund cutting-edge medical research. For BiomX, a company working with bacteriophages to treat infections, this determines the availability of capital. Economic growth stimulates investment in breakthrough biotech platforms, while a downturn can significantly slow it.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772585277962 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BiomX Inc.
BiomX is a company developing bacteriophage-based therapies to combat bacterial infections. This figure reflects the market valuation of its scientific platform. It is a bet that its approach will become an alternative to traditional antibiotics.
P/S market segment - Pharma infections
BiomX is a biopharmaceutical company developing phage-based (bacteria-infecting viruses) treatments for chronic bacterial diseases. This chart shows the average valuation in the infectious diseases sector. It reflects investor interest in new approaches to combating bacterial infections, particularly those resistant to antibiotics.
P/S of the market as a whole
BiomX Inc. is a biotech company developing bacteriophage-based drugs (bacteria-killing viruses) for the treatment of chronic bacterial diseases such as acne and atopic dermatitis. Its valuation reflects its belief in the potential of phage therapy. This chart helps assess how the market values new approaches in medicine.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BiomX Inc.
BiomX is a biotech company developing phage-based therapies (viruses that infect bacteria) for the treatment of chronic diseases. Future revenue depends on the success of this innovative technology. The chart shows how much investors believe phage therapy will become a new standard in medicine.
%20P%2FS%20BiomX%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BiomX-Inc.&v=1772585278147 "The graph of the company's future (projected) P/S BiomX Inc.")
Future (projected) P/S of the market segment - Pharma infections
BiomX Inc. is a biotech company developing drugs based on bacteriophages (viruses that infect bacteria) to treat diseases caused by specific bacteria, such as acne and cystic fibrosis. This chart shows how investors view the potential of this innovative antibacterial therapy compared to other pharmaceutical companies.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20infections&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-infections&v=1772585278180 "Future (projected) P/S market segment graph - Pharma infections")
Future (projected) P/S of the market as a whole
This chart reflects expectations for the biotech sector. For BiomX, a company developing bacteriophage-based therapies to combat bacterial infections, it's an indicator of interest in new approaches. Market optimism is helping fund alternatives to antibiotics, which is becoming increasingly important due to the rise of bacterial resistance.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772585278194 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BiomX Inc.
BiomX is a clinical-stage biopharmaceutical company developing phage-based (bacteria-infecting viruses) therapies for the treatment of chronic bacterial diseases such as acne and atopic dermatitis. This chart reflects revenue from partnerships. Future revenue is dependent on the success of clinical trials and the commercialization of this innovative therapy.
Sales of companies in the market segment - Pharma infections
BiomX Inc. is a biotechnology company developing bacteriophage-based drugs to treat diseases caused by specific bacteria. This chart shows the growth of the infection treatment market. Phage therapy is a promising alternative to antibiotics, and BiomX is at the forefront of this innovative medical field.
Overall market sales
BiomX Inc. is a biotechnology company developing bacteriophage-based drugs to treat antibiotic-resistant infections. Its development depends on successful research. The overall economic situation, shown in this chart, influences the flow of investment into the biotechnology sector to address global health issues.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BiomX Inc.
BiomX is a clinical-stage biopharmaceutical company developing bacteriophage-based therapies (viruses that infect bacteria) for the treatment of chronic bacterial diseases such as acne and atopic dermatitis. This chart reflects analysts' expectations for the commercial potential of this innovative approach to treating bacterial infections.
%20sales%20of%20the%20company%20BiomX%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BiomX-Inc.&v=1772585278437 "Schedule of future (projected) sales of the company BiomX Inc.")
Future (projected) sales of companies in the market segment - Pharma infections
BiomX is a biotechnology company developing bacteriophage-based drugs for the treatment of chronic diseases caused by bacteria. This chart shows expectations for the infectious disease pharmaceutical sector, reflecting the growing interest in new approaches to combating bacteria in the era of antibiotic resistance.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-infections&v=1772585278503 "Schedule of future (projected) sales of companies in the market segment - Pharma infections")
Future (projected) sales of the market as a whole
BiomX Inc. is a clinical-stage biopharmaceutical company developing bacteriophage-based treatments for chronic diseases caused by bacteria. Its success depends on the results of clinical trials. This graph, reflecting the state of the economy, affects the availability of capital for funding innovative medical approaches such as phage therapy.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772585278620 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BiomX Inc.
BiomX is developing bacteriophage-based therapies (viruses that infect bacteria) to treat microbiome-related diseases. The chart shows the company's financial performance at the clinical trial stage. Negative values represent investments in this cutting-edge field of science, which could offer new solutions for fighting resistant infections.
Market segment marginality - Pharma infections
BiomX develops bacteriophage-based therapeutics for the treatment of infectious diseases caused by resistant bacteria. This chart serves as a benchmark for the biotech company. It shows the average profitability in its sector, illustrating the potential profitability BiomX aspires to achieve if its innovative drugs are successful.
Market marginality as a whole
BiomX is a biopharmaceutical company developing bacteriophage-based treatments for chronic bacterial diseases. This total market profitability graph does not impact its operations. BiomX's success depends on its unique scientific platform and its ability to demonstrate the efficacy of phage therapy in clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company BiomX Inc.
BiomX is a biotechnology company developing bacteriophage-based therapies for the treatment of microbiome-related diseases. This graph shows the team of microbiologists and clinicians. Their numbers reflect the progress of research and clinical trials of this innovative approach.
Share of the company's employees BiomX Inc. within the market segment - Pharma infections
BiomX is a pioneer in developing bacteriophage-based therapies to combat bacterial infections. This chart shows the percentage of leading microbiologists and phage therapy specialists the company has attracted to this innovative field. It reflects its concentration of unique scientific expertise in creating an alternative to antibiotics.
Number of employees in the market segment - Pharma infections
BiomX is a biotech company developing bacteriophage-based therapies (viruses that infect bacteria) to treat microbiome-related diseases. This graph illustrates how new scientific discoveries (in this case, about the role of the microbiome) are leading to the creation of entire companies and new treatment approaches, requiring unique microbiologists.
Number of employees in the market as a whole
BiomX Inc. fights infections, and its relevance is growing in a world facing pandemics. This chart reflects the state of the economy, whose stability depends on the healthcare system. The work of companies like BiomX is an element of national security and supports the demand for microbiologists and infectious disease specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BiomX Inc. (PHGE)
BiomX is a biotech company developing phage-based therapies (viruses that attack bacteria). This chart represents the net intellectual capital valuation. The company's value is based on its unique scientific platform for phage discovery and production. The chart shows how highly the market values this innovative approach to treating infections, calculated on a per-scientist basis.
%20of%20the%20company%20BiomX%20Inc.%20(PHGE)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BiomX-Inc.-PHGE&v=1772585278925 "Chart of market capitalization per employee (in thousands of dollars) of the company BiomX Inc. (PHGE)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma infections
BiomX Inc. is developing bacteriophage-based therapies to combat infections. This is a cutting-edge field of microbiology. The chart shows the market's perceived value in a team of scientists working with this complex technology. A comparison with the industry allows one to assess how unique and promising their scientific approach is considered.
%20by%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-infections&v=1772585278939 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma infections")
Market capitalization per employee (in thousands of dollars) for the overall market
BiomX Inc. is a biopharmaceutical company developing phage-based treatments for chronic diseases. This chart shows the average market value of each employee's contribution. It illustrates how the market values innovative approaches in medicine.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772585278972 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BiomX Inc. (PHGE)
BiomX is a biotech company developing phage-based therapies (bacteria-killing viruses). This is a cutting-edge area of R&D. This chart shows the net loss per employee. It reflects how much the company is "burning" per scientist to develop this new class of drugs.
%20Chart%20BiomX%20Inc.%20(PHGE)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BiomX-Inc.-PHGE&v=1772585279011 "Company Profit Per Employee (in thousands of dollars) Chart BiomX Inc. (PHGE)")
Profit per employee (in thousands of dollars) in the market segment - Pharma infections
BiomX Inc. is a biotech company developing bacteriophage-based drugs for the treatment of chronic bacterial diseases. Its strength lies in its scientific platform and team of microbiologists. This graph likely shows negative profit per employee, which is typical for companies in clinical trials that incur significant R&D costs while awaiting approval for their products.
%20in%20the%20market%20segment%20-%20Pharma%20infections&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-infections&v=1772585279041 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma infections")
Profit per employee (in thousands of dollars) for the market as a whole
BiomX (PHGE) is an Israeli clinical-stage biotech company developing bacteriophage-based therapies (bacteria-killing viruses) for the treatment of chronic diseases such as acne and cystic fibrosis. It's an R&D company. This chart shows the average profitability per employee across the market. For PHGE (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772585279078 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BiomX Inc. (PHGE)
BiomX is a biotech company developing bacteriophage-based therapies to combat infections. This graph depicts the path of this innovative therapy to patients. For a company working with cutting-edge technologies, it shows the future potential if its approach is successful and commercialized.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BiomX-Inc.-PHGE&v=1772585279127 "Sales chart per company employee BiomX Inc. (PHGE)")
Sales per employee in the market segment - Pharma infections
BiomX (PHGE) is a biotech company developing phage-based therapies (viruses that attack bacteria) for the treatment of chronic diseases (e.g., acne, cystic fibrosis). This is R&D. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of BiomX's workforce.
Sales per employee for the market as a whole
BiomX is a biotech company developing phage-based therapies (viruses that attack bacteria) for the treatment of microbiome-related diseases (e.g., acne, IBD). The company has no commercial revenue, which is irrelevant. Their value lies in the potential of their unique R&D platform.
Short shares by company, segment and market as a whole
Shares shorted by company BiomX Inc. (PHGE)
BiomX is a biotech company specializing in phage therapy (using viruses to kill bacteria). It's a promising but complex field. The company has had some setbacks in trials. This chart shows the odds that their approach won't work. "Bears" believe phage therapy is too complex to commercialize.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BiomX-Inc.-PHGE&v=1772585279252 "Short Shares Chart for the Company BiomX Inc. (PHGE)")
Shares shorted by market segment - Pharma infections
BiomX Inc. (PHGE) is a biotech company developing bacteriophage-based therapies (bacteria-killing viruses) for the treatment of chronic diseases such as acne and cystic fibrosis. This chart shows the overall short position in the infectious disease-focused biotech sector. Its rise reflects investor skepticism about this new phage technology and its approval.
Shares shorted by the overall market
BiomX is a biotech company developing bacteriophage-based therapies (for acne treatment, ABC). This chart illustrates the overall market pessimism. This is an innovative, but niche, area of R&D. When investors are fearful, they are unwilling to fund such long-term projects, preferring companies with clear revenues.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BiomX Inc. (PHGE)
This chart for BiomX is a barometer of faith in phage therapy. The company is developing "cocktails" of bacteriophages (bacteria-killing viruses) to treat acne, atopic dermatitis, and other diseases. "Overheating" (above 70) occurs due to positive Phase 2 data. The complexity of phage production and the risk of failure in later phases lead to "oversold" conditions.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BiomX-Inc.-PHGE&v=1772585279383 "RSI 14 indicator chart for the company's stock BiomX Inc. (PHGE)")
RSI 14 Market Segment - Pharma infections
BiomX (PHGE) is a superbug "killer" (Israel). They (like Armata) use *bacteriophages* (phages)—"viruses" that *specifically* "eat" *bacteria* (acne, IBD). The "Pharma infections" (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this *entire* segment. It helps us understand: is PHGE's growth due to their R&D, or is *the entire* biotech sector "overheated"?
RSI 14 for the overall market
BiomX (PHGE) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PHGE (BiomX Inc.)
BiomX is a biotech company developing phage-based therapies (bacteria-killing viruses) for chronic diseases such as acne, atopic dermatitis, and cystic fibrosis. This chart shows the analysts' average 12-month forecast, reflecting their speculative bet on the success of this R&D platform.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PHGE-BiomX-Inc.&v=1772585279533 "A chart showing analyst consensus forecasts for the expected stock price. PHGE (BiomX Inc.)")
The difference between the consensus estimate and the actual stock price PHGE (BiomX Inc.)
BiomX is a biotech company developing "phage therapy" (viruses against bacteria). Their goal is to treat acne, atopic dermatitis, and other chronic diseases. This chart shows how the current stock price differs from the "fair" value predicted by analysts. It reflects their faith in this "post-antibiotic" technology.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PHGE-BiomX-Inc.&v=1772585279569 "A chart showing the difference between the consensus forecast and the actual stock price. PHGE (BiomX Inc.)")
Analyst consensus forecast for stock prices by market segment - Pharma infections
BiomX is a bacteria hunter. The company develops "bacteriophages" (bacteria-killing viruses) for the treatment of acne and cystic fibrosis. This chart reflects analysts' overall expectations for the entire infectious pharmaceutical sector. It shows whether experts believe phage therapy can be an alternative to antibiotics.
Analysts' consensus forecast for the overall market share price
BiomX is an Israeli biotech company developing "phage therapy"—the use of viruses (bacteriophages) to destroy harmful bacteria that cause acne and infections. This chart shows the overall "risk appetite" in the market. For BiomX, a company with an innovative but risky platform, overall market optimism (risk appetite) is critical for R&D funding.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BiomX Inc.
BiomX is a superbug killer. They are a pioneer in phage therapy—the use of viruses (bacteriophages) to precisely attack and destroy harmful bacteria (those causing acne and COPD) while sparing the good ones. This graph is a clear indicator of faith in their R&D. It reflects their progress in clinical trials and their ability to develop phages into an FDA-approved drug.
AKIMA Market Segment Index - Pharma infections
BiomX (PHGE) is an Israeli biotech company specializing in phage therapy. They program bacteriophages (bacteria-infecting viruses) to precisely destroy harmful bacteria for the treatment of acne, cystic fibrosis, and gastrointestinal disorders. The chart shows the average index for the segment, helping investors assess how this cutting-edge technology compares to the average market.
The AKIM Index for the overall market
BiomX is an Israeli biotech company using bacteriophages (bacteria-killing viruses) to treat infections and chronic diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific platform compares to overall economic trends and the problem of antibiotic resistance.
